Majolo, F.; Silva, G.L.d.; Vieira, L.; Anli, C.; Timmers, L.F.S.M.; Laufer, S.; Goettert, M.I.
Neuropsychiatric Disorders and COVID-19: What We Know So Far. Pharmaceuticals 2021, 14, 933.
https://doi.org/10.3390/ph14090933
AMA Style
Majolo F, Silva GLd, Vieira L, Anli C, Timmers LFSM, Laufer S, Goettert MI.
Neuropsychiatric Disorders and COVID-19: What We Know So Far. Pharmaceuticals. 2021; 14(9):933.
https://doi.org/10.3390/ph14090933
Chicago/Turabian Style
Majolo, Fernanda, Guilherme Liberato da Silva, Lucas Vieira, Cetin Anli, LuÃs Fernando Saraiva Macedo Timmers, Stefan Laufer, and Márcia Inês Goettert.
2021. "Neuropsychiatric Disorders and COVID-19: What We Know So Far" Pharmaceuticals 14, no. 9: 933.
https://doi.org/10.3390/ph14090933
APA Style
Majolo, F., Silva, G. L. d., Vieira, L., Anli, C., Timmers, L. F. S. M., Laufer, S., & Goettert, M. I.
(2021). Neuropsychiatric Disorders and COVID-19: What We Know So Far. Pharmaceuticals, 14(9), 933.
https://doi.org/10.3390/ph14090933